Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
Study Identifier
M22-394
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female
Age
18 - 45 Years
Protocol Summary
This study will assess adverse events and compare how ubrogepant and atogepant tablets move through the body of healthy adult lactating female participants.
Ubrogepant and atogepant are approved drugs for treatment of migraine in adults. Participants will be assigned to one of the 2 treatment arms to receive atogepant or ubrogepant. Approximately 24 healthy adult lactating female participants will be enrolled at 3 sites in the United States
Participants will receive oral tablets of ubrogepant or atogepant on Day 1 and will be followed for 30 days.
Study Locations
Location
Status
Location
Bio-Kinetic Clinical Applications, LLC /ID# 255452
Springfield, Missouri, United States, 65802
Status
Not applicable
Location
Icon /Id# 257524
San Antonio, Texas, United States, 78209
Status
Not applicable
Location
Icon /Id# 257525
Salt Lake City, Utah, United States, 84124
Status
Not applicable